Multiplex Assays Market (2026 - 2035)

ID: MRFR/HC/4677-HCR 90 Pages Rahul Gotadki Last Updated: October 29, 2026
The global Multiplex Assays Market is anticipated to reach USD 6.84 Billion by 2035, growing at a CAGR of 13.6%, driven by rapid technological advancements in multiplex assay platforms, increasing demand for point-of-care and personalized diagnostics, the rising prevalence of chronic and infectious diseases, and expanding applications in clinical diagnostics and drug discovery.
Multiplex Assays Market
Market Size
Forecast Period2026-2035
CAGR (2026-2035)13.6%
2025 Market SizeUSD 1.90 Billion
2035 Market SizeUSD 6.84 Billion
Key Players
Thermo Fisher Scientific
Bio-Rad Laboratories
bioMérieux
Illumina
DiaSorin
BD
Opportunities
  • Decentralized Syndromic Panels for Emerging Markets
  • Data Monetization and Assay-as-a-Service Models
  • Multiomics and Spatial Biology Integration
  1. 1 Market Summary | |
  2. 2 Key Report Takeaways | |
    1. 2.1 By Type | |
    2. 2.2 By Technology | |
    3. 2.3 By Application | |
    4. 2.4 By End-User | |
    5. 2.5 By Region | |
  3. 3 Market Size and Forecast (2021–2035) | |
    1. 3.1 Historical Market Size (2021–2024) | |
    2. 3.2 Base Year and Forecast Market Size (2025–2035) | |
    3. 3.3 Year-over-Year Growth Analysis | |
  4. 4 Driver Impact Analysis | |
    1. 4.1 Syndromic Infectious Disease Testing and Antimicrobial Stewardship | |
    2. 4.2 Expansion of Precision Oncology and Companion Diagnostics | |
    3. 4.3 Biomarker-Driven Clinical Development and Outsourcing | |
    4. 4.4 Proteomics and Multiomics Platform Innovation | |
    5. 4.5 Public Biomedical Research Funding | |
    6. 4.6 Laboratory Capacity Build-Out in Asia-Pacific | |
  5. 5 Restraints Impact Analysis | |
    1. 5.1 High Capital and Per-Sample Costs of Advanced Platforms | |
    2. 5.2 Reimbursement Limits on Large Syndromic Panels | |
    3. 5.3 Regulatory Complexity Under IVDR and Evolving U.S. Oversight | |
    4. 5.4 Cross-Reactivity and Inter-Platform Standardization Gaps | |
    5. 5.5 Shortage of Skilled Laboratory and Data-Analysis Staff | |
  6. 6 Opportunities | |
    1. 6.1 Decentralized Syndromic Panels for Emerging Markets | |
    2. 6.2 Data Monetization and Assay-as-a-Service Models | |
    3. 6.3 Multiomics and Spatial Biology Integration | |
    4. 6.4 CLIA-Waived and Near-Patient Panels | |
    5. 6.5 IVDR-Ready Kits for European Laboratories | |
  7. 7 Regional Market Share and Country-Level Analysis | |
    1. 7.1 North America | | |
      1. 7.1.1 United States | | |
      2. 7.1.2 Canada | | |
      3. 7.1.3 Mexico | |
    2. 7.2 Europe | | |
      1. 7.2.1 Germany | | |
      2. 7.2.2 United Kingdom | | |
      3. 7.2.3 France | | |
      4. 7.2.4 Italy | | |
      5. 7.2.5 Spain | | |
      6. 7.2.6 Rest of Europe | |
    3. 7.3 Asia-Pacific | | |
      1. 7.3.1 China | | |
      2. 7.3.2 Japan | | |
      3. 7.3.3 India | | |
      4. 7.3.4 Australia | | |
      5. 7.3.5 South Korea | | |
      6. 7.3.6 Rest of Asia-Pacific | |
    4. 7.4 South America | | |
      1. 7.4.1 Brazil | | |
      2. 7.4.2 Argentina | | |
      3. 7.4.3 Rest of South America | |
    5. 7.5 Middle East and Africa | | |
      1. 7.5.1 GCC | | |
      2. 7.5.2 South Africa | | |
      3. 7.5.3 Rest of Middle East and Africa | |
  8. 8 Future Outlook (2026–2035) | |
    1. 8.1 AI-Assisted Panel Design and Automated Analysis | |
    2. 8.2 Platform Economics and Recurring Consumables | |
    3. 8.3 Multiomics Convergence in Precision Medicine | |
    4. 8.4 Infectious Disease Preparedness and AMR Surveillance | |
  9. 9 Segmentation Analysis | |
    1. 9.1 By Type | | |
      1. 9.1.1 Cell-based multiplex assays | | |
      2. 9.1.2 Protein multiplex assays | | |
      3. 9.1.3 Nucleic-acid multiplex assays | | |
      4. 9.1.4 Bead-based immunoassays | |
    2. 9.2 By Technology | | |
      1. 9.2.1 Multiplex real-time PCR | | |
      2. 9.2.2 Flow cytometry | | |
      3. 9.2.3 Bead-based xMAP/Luminex | | |
      4. 9.2.4 Next-generation sequencing-based | | |
      5. 9.2.5 Mass cytometry (CyTOF) | | |
      6. 9.2.6 Microarray & others | |
    3. 9.3 By Application | | |
      1. 9.3.1 Infectious disease diagnostics | | |
      2. 9.3.2 Oncology & companion diagnostics | | |
      3. 9.3.3 Autoimmune & allergy testing | | |
      4. 9.3.4 Drug discovery & biomarker validation | | |
      5. 9.3.5 Others | |
    4. 9.4 By End-User | | |
      1. 9.4.1 Pharmaceutical & biopharmaceutical companies | | |
      2. 9.4.2 Academic & research institutes | | |
      3. 9.4.3 Contract research organizations | | |
      4. 9.4.4 Hospitals & diagnostic laboratories | | |
      5. 9.4.5 Others | |
  10. 10 Competitive Landscape | |
    1. 10.1 Market Concentration Analysis | |
    2. 10.2 Competitive Benchmarking | |
    3. 10.3 Company Profiles | | |
      1. 10.3.1 Thermo Fisher Scientific | | |
      2. 10.3.2 Bio-Rad Laboratories | | |
      3. 10.3.3 bioMérieux | | |
      4. 10.3.4 Illumina | | |
      5. 10.3.5 DiaSorin (Luminex) | | |
      6. 10.3.6 BD (Becton Dickinson) | | |
      7. 10.3.7 QIAGEN | | |
      8. 10.3.8 Merck KGaA | | |
      9. 10.3.9 Revvity | | |
      10. 10.3.10 Meso Scale Diagnostics | | |
      11. 10.3.11 Agilent Technologies | | |
      12. 10.3.12 Standard BioTools | |
  11. 11 Recent News & Developments | |
  12. 12 Report Scope and Methodology | |
  13. 13 Detailed Sources and Citations | |
  14. 14 Frequently Asked Questions (FAQs) | | LIST OF TABLES | |
  15. TABLE 1 Market Snapshot – Key Metrics, 2025–2035 | |
  16. TABLE 2 Global Market Size & Forecast, by Revenue (USD Billion), 2021–2035 | |
  17. TABLE 3 Driver Impact Analysis, 2026–2035 | |
  18. TABLE 4 Restraints Impact Analysis, 2026–2035 | |
  19. TABLE 5 Regional Summary, 2025 | |
  20. TABLE 6 North America Market, by Country, 2025 | |
  21. TABLE 7 Europe Market, by Country, 2025 | |
  22. TABLE 8 Asia-Pacific Market, by Country, 2025 | |
  23. TABLE 9 South America Market, by Country, 2025 | |
  24. TABLE 10 Middle East and Africa Market, by Country, 2025 | |
  25. TABLE 11 Global Market, by Type, 2025 | |
  26. TABLE 12 Global Market, by Technology, 2025 | |
  27. TABLE 13 Global Market, by Application, 2025 | |
  28. TABLE 14 Global Market, by End-User, 2025 | |
  29. TABLE 15 Competitive Benchmarking Matrix, 2025 | |
  30. TABLE 16 Report Scope and Methodology | |
  31. TABLE 17 Detailed Sources and Citations | |
  32. TABLE 18 Segmentation Quick Reference | |
  33. TABLE 19 Sub-Segment Key Trends, by Dimension | | LIST OF FIGURES | |
  34. FIGURE 1 Market Dynamics – Drivers, Restraints and Opportunities | |
  35. FIGURE 2 Industry Value Chain Analysis | |
  36. FIGURE 3 Porter's Five Forces Analysis | |
  37. FIGURE 4 Global Market Size Trend, 2021–2035 (USD Billion) | |
  38. FIGURE 5 Year-over-Year Growth Rate, 2022–2035 | |
  39. FIGURE 6 Market Share by Type, 2025 | |
  40. FIGURE 7 Market Share by Technology, 2025 | |
  41. FIGURE 8 Market Share by Application, 2025 | |
  42. FIGURE 9 Market Share by End-User, 2025 | |
  43. FIGURE 10 Regional Market Share, 2025 | |
  44. FIGURE 11 Regional Growth Comparison, 2026–2035 | |
  45. FIGURE 12 Competitive Landscape – Estimated Revenue Share Ranges, 2025 | |
  46. FIGURE 13 Market Concentration and Positioning Matrix

Segmentation Quick Reference

DimensionSub-SegmentsDominant SegmentFastest Growing Segment
By TypeCell-based multiplex assays, Protein multiplex assays, Nucleic-acid multiplex assays, Bead-based immunoassaysProtein multiplex assays (38.2% share)Nucleic-acid multiplex assays (15.7% CAGR)
By TechnologyMultiplex real-time PCR, Flow cytometry, Bead-based xMAP/Luminex, Next-generation sequencing-based, Mass cytometry (CyTOF), Microarray & othersFlow cytometry (29.8% share)Mass cytometry (CyTOF) (14.0% CAGR)
By ApplicationInfectious disease diagnostics, Oncology & companion diagnostics, Autoimmune & allergy testing, Drug discovery & biomarker validation, OthersInfectious disease diagnostics (35.7% share)Oncology & companion diagnostics (15.2% CAGR)
By End-UserPharmaceutical & biopharmaceutical companies, Academic & research institutes, Contract research organizations, Hospitals & diagnostic laboratories, OthersPharmaceutical & biopharmaceutical companies (42.9% share)Contract research organizations (16.3% CAGR)
By RegionNorth America, Europe, Asia-Pacific, South America, Middle East and AfricaNorth America (41.5% share)Asia-Pacific (16.2% CAGR)

Market Segmentation Overview

By Type

Sub-SegmentKey Trend
Cell-based multiplex assaysFunctional immune profiling for immuno-oncology programs
Protein multiplex assaysProximity extension and aptamer panels scaling to thousands of targets
Nucleic-acid multiplex assaysSequencing and CRISPR panels expanding into transplant and pathogen genotyping
Bead-based immunoassaysMicroliter-sample cytokine quantification in trials

Protein multiplex assays lead the type dimension because cytokine and target-engagement panels are embedded in nearly every stage of drug development. Nucleic-acid multiplex assays grow fastest, helped by regulatory acceptance of large genomic companion diagnostics and new uses in transplant monitoring. Bead-based immunoassays and Cell-based multiplex assays remain essential for quantification and functional readouts that sequencing cannot provide.

By Technology

Sub-SegmentKey Trend
Multiplex real-time PCRTiered syndromic panels shaped by payer coverage limits
Flow cytometrySpectral unmixing and imaging extend instrument life
Bead-based xMAP/LuminexOpen platform licensed across many panel suppliers
Next-generation sequencing-basedComprehensive genomic profiling for therapy selection
Mass cytometry (CyTOF)40-plus-marker single-cell panels entering clinical trials
Microarray & othersStable niches in gene expression and allergen arrays

Flow cytometry holds the largest technology share because hospitals and research cores already own large fleets that spectral and imaging upgrades keep relevant. Mass cytometry (CyTOF) grows fastest since metal-tagged antibodies avoid spectral overlap and support deeper immune profiling in trials. Multiplex real-time PCR keeps its syndromic stronghold, though payer limits on large panels are pushing suppliers toward smaller, tiered designs.

By Application

Sub-SegmentKey Trend
Infectious disease diagnosticsOne-hour syndromic panels supporting antibiotic stewardship
Oncology & companion diagnosticsPan-cancer profiling tests tied to targeted therapies
Autoimmune & allergy testingComponent-resolved panels moving into primary care
Drug discovery & biomarker validationMultiplex safety and efficacy readouts in lead optimization
OthersMetabolic, cardiovascular and transplant monitoring panels

Infectious disease diagnostics leads applications because hospitals use multi-pathogen panels to cut time to targeted therapy and reduce empiric antibiotic use. Oncology & companion diagnostics grows fastest as each new targeted drug adds biomarkers that must be tested before prescription. Drug discovery & biomarker validation provides steady pharmaceutical demand, while Autoimmune & allergy testing benefits from broader panels in routine clinical care.

By End-User

Sub-SegmentKey Trend
Pharmaceutical & biopharmaceutical companiesBiomarker-guided trial designs and regulatory submissions
Academic & research institutesGrant-funded early adoption of new chemistries
Contract research organizationsOutsourced panel validation and global sample logistics
Hospitals & diagnostic laboratoriesRoutine syndromic and oncology panel testing
OthersBiotech start-ups and public health laboratories

Pharmaceutical & biopharmaceutical companies are the largest buyers, using multiplex panels for patient stratification and pharmacodynamic endpoints in regulatory filings. Contract research organizations grow fastest because sponsors prefer to outsource validated assays across global trial sites instead of duplicating instrument fleets. Academic & research institutes and Hospitals & diagnostic laboratories round out demand, with the former driving method innovation and the latter converting validated panels into routine care.

Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.